Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity

2 Apr 2009 07:00

RNS Number : 9727P
ViaLogy PLC
02 April 2009
 



VIALOGY PLC ("VIALOGY" OR "THE COMPANY")

VIALOGY TO RAISE UP TO £1.5 MILLION

LONDONApril 2, 2009 - ViaLogy PLC (LSE: VIY).  The Company today announces it is to offer investors who participated in ViaLogy's 2007 and 2008 funding rounds the opportunity to exercise their warrants at a reduced price.  It is proposed that the 27,500,000 warrants issued in October 2007 ("2009 Warrants") exercisable at 10 pence per Ordinary Share will be exercisable at 2.5 pence until noon on Thursday, 30 April 2009 (the "End Date") It is further proposed that the 45,000,000 warrants issued in October 2008 ("2010 Warrants") exercisable at 5 pence per Ordinary Share will be exercisable at 2 pence until the End Date In addition, for the 1,193,654 warrants held by George Rehm and Michael Kelly, both Directors, (exercisable at 4 pence per share) and a total of 2,500,000 warrants held by Dr Richard Dixey and Mark Tompkins (exercisable at 6 pence per share) will be reduced to 2 pence per share during the same period.

Full exercise of all outstanding 2009 Warrants and 2010 Warrants prior to the End Date, at the reduced subscription prices, would raise £1,587,500 (before expenses) for the Company. After the End Date, the original subscription prices relating to all such warrants will apply.

In accordance with the terms of their constitution, the proposed variation of the subscription prices applying to the 2009 Warrants and 2010 Warrants must be approved by, and is conditional upon the passing of, extraordinary resolutions to be proposed at meetings of the holders of such warrants. Accordingly, the Company has today convened meetings of the holders of the 2009 Warrants and the 2010 Warrants to be held on Monday, 20 April 2009.

The Company has also today entered into agreements with certain institutions and individuals ("Subscribers") who have undertaken to subscribe for such number of new Ordinary Shares ("Subscriber Shares") as has an aggregate subscription price of £1,587,500, less the aggregate amount of the proceeds of the exercise of warrants by warrant holders (the "Subscription").  The aggregate number of Ordinary Shares to be subscribed by such persons shall not, however, exceed 50,377,300 (representing approximately 10 per cent. of the Company's current issued share capital), which is the maximum number of Ordinary Shares the Directors are authorised to issue for cash, pursuant to resolutions passed at the Annual General Meeting of the Company held on 29 October 2008, other than pro rata to existing shareholders. The subscription price payable for the Subscriber Shares will be determined by the number of warrants which holders of the 2009 Warrants and 2010 Warrants elect to exercise, but shall be not less than 2 pence for the first 45 million Subscriber Shares and 2.5 pence for the remaining Subscriber Shares.

In consideration of the Subscribers agreeing to subscribe for the Subscriber Shares, and so guarantee that the amount of funds to be received by ViaLogy pursuant to the proposed fundraising, (before expenses) is not less than £1,034,432.50, the Company has agreed to pay to such Subscribers an aggregate fee of £79,375 being 5% of £1,587,500, which is the maximum amount to be raised by the Company, assuming full exercise of the 2009 Warrants and the 2010 Warrants. 

Application will be made for the Ordinary Shares issued upon the valid exercise of outstanding warrants and the Subscriber Shares to be admitted to trading on AIM.

"The board decided to re-price the warrants in conjunction with the Subscription for two main reasons," said ViaLogy chairman Terry Bond. "Firstly, shareholder dilution is minimised because the warrants are already accounted for in the Company's fully diluted financial position.  Secondly, ViaLogy needs additional funding for future on-going expenditure, including the opportunity to increase our financial participation in the successful well our QuantumRD technology has identified on the Galba Oil Prospect in south central Texas.  Atascosa Exploration LLC, who commissioned us to analyse the seismic data and advise on drilling locations, were so pleased with the results that they offered us very attractive terms to double ViaLogy's working interest in the first well production to 10%. The re-pricing of the warrants seemed a very elegant solution to our funding requirements whilst minimising any dilution effect."

Ends

For further information please contact:

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807) Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756)

Nominated Advisor (Seymour Pierce)   Mark Percy +44 (0) 20-7107-8000 

Brokers to ViaLogy PLC (St. Helen's Capital)

Ruari McGirr / Sebastian Wykeham +44 (0) 7628 5582 

About ViaLogy

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications.  ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential.  ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter.  This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications.  For more information, visit our website at www.ViaLogy.com. 

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEDGGDSBUGGGCB
Date   Source Headline
6th Apr 20204:40 pmRNSSecond Price Monitoring Extn
6th Apr 20204:36 pmRNSPrice Monitoring Extension
27th Mar 20203:00 pmRNSIssue of Share Options
25th Mar 20207:00 amRNSContract manufacturing agreement for COVID-19 test
16th Mar 20204:41 pmRNSSecond Price Monitoring Extn
16th Mar 20204:36 pmRNSPrice Monitoring Extension
13th Mar 202011:51 amRNSHolding(s) in Company
10th Mar 20207:00 amRNSAcquisition of French distribution channel
17th Feb 20207:00 amRNSCE Marking Technical File submission
14th Feb 202011:00 amRNSMedilink Award win for Outstanding Achievement
14th Feb 20207:00 amRNSTGA approves DPYD for sale in Australia
5th Dec 201912:10 pmRNSThe Healthcare+ Expo Taiwan
2nd Dec 20197:00 amRNSHalf-year Report
29th Nov 201912:05 pmRNSBionow Double Award Win
28th Nov 20197:00 amRNSOpening of New Facilities and Corporate HQ
15th Nov 20197:00 amRNSPrivate Investor Presentation
12th Nov 201910:12 amRNSNotice of Results
6th Nov 20191:52 pmRNSCapital Markets Day
1st Nov 20197:00 amRNSDirector/PDMR Shareholding
31st Oct 20197:00 amRNSLaunch of Yourgene FlexT Analysis Software
30th Oct 20197:00 amRNSIssue of Share Options
15th Oct 20197:00 amRNSAmerican Society of Human Genetics Annual Meeting
14th Oct 20197:00 amRNSHalf year trading update
1st Oct 20197:00 amRNSPrivate Investor Presentation
26th Sep 20197:00 amRNSCE-IVD Certification renewal
18th Sep 20197:00 amRNSLaunch of DPYD chemotoxicity diagnostic assay
17th Sep 20195:50 pmRNSResult of AGM
17th Sep 20197:00 amRNSAGM Statement
20th Aug 20197:00 amRNSNotice of AGM
19th Aug 201910:35 amRNSChange of Registered Office
16th Aug 20193:49 pmRNSHolding(s) in Company
16th Aug 20199:06 amRNSDirectorate Change
12th Aug 20197:00 amRNSAmendment to Share Options
1st Aug 20197:00 amRNSDirector/PDMR Shareholding
29th Jul 20197:00 amRNSAppointment of Director
10th Jul 20197:00 amRNSFinal Results, Business Update and Director Change
27th Jun 20197:00 amRNSNotice of Results
24th Jun 20197:00 amRNSYourgene participates in key global conferences
3rd Jun 20197:01 amRNSDirector's dealing
3rd Jun 20197:00 amRNSIssue of Share Options
9th May 20194:07 pmRNSDirector's dealing
9th May 20197:00 amRNSDirectors' dealing & warrant extension
1st May 20198:05 amRNSTotal Voting Rights
26th Apr 20195:12 pmRNSHolding(s) in Company
26th Apr 20195:01 pmRNSHolding(s) in Company
25th Apr 20194:40 pmRNSCompletion of Acquisition
18th Apr 20197:00 amRNSResults of Placing and Subscription
17th Apr 20194:50 pmRNSAppointment of Sole Corporate Broker
17th Apr 20194:48 pmRNSProposed Acquisition, Placing & Subscription
8th Apr 20197:00 amRNSFull-year Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.